Fu WeiCEO at CBC Group
Fu Wei founded CBC Group, Asia’s largest healthcare-dedicated asset management firm, in 2014. He serves as the Chief Executive Officer of the firm, oversees the firm’s overall strategy, talent development and assumes the responsibilities in maintaining the firm’s long-term partnership with global investors. He led the firm’s investment transactions and was instrumental in incubating several biotech and pharmaceutical companies, including I-MAB (Nasdaq: IMAB), Everest Medicines (1952.HK), Jadeite Medicines (Japan), RVAC Medicines (Singapore), A-BioX (U.S.) and Ensem Therapeutics (U.S.). He is the Chairman of the Board at Everest Medicines and an Independent Director of I-MAB.
Fu has over 18 years of private equity and investment banking experience. Prior to founding CBC Group, Fu was formerly the General Manager of the investment department at a wholly owned subsidiary of Far East Horizon Limited (HKEX:3360). He also worked for Standard Chartered Bank (China), Macquarie Capital (Singapore) and Temasek Holdings.
Fu was named China’s Top 30 Investors in 2021 by Forbes China and under his leadership, CBC Group’s AUM grew from US$180 million in 2014 to today’s US$ 6.7 billion.
Fu received his bachelor’s degree in electrical and electronic engineering from Nanyang Technological University in Singapore in February 2005. He is a scholar of Singapore's Ministry of Education, and he is a holder of the prestigious YPO membership (only available to individuals holding the top position of a qualifying company).